NLS pharma-clinical-trial-box

Ultimovacs has announced continuing positive efficacy data in its ongoing US-based phase I clinical trial, UV1-103. The study evaluates the company’s universal cancer vaccine, UV1, in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab, as first-line treatment in advanced non-resectable and metastatic malignant melanoma patients. “Given the historic trajectory for patients with metastatic malignant melanoma, this […]

Alligator Bioscience has reported positive safety data from the 900 mg dose cohort in its Phase 1, first-in-human clinical trial with the 4-1BB (CD137) targeting drug candidate, ATOR-1017. ATOR-1017 is being developed as a tumor-directed therapy for advanced/metastatic cancer. The data show that for doses up to 900 mg there were no significant safety concerns […]

BioArctic’s partner Eisai has announced results for the large global Phase 3 confirmatory Clarity AD study in 1,795 subjects. The study met the primary endpoint showing a highly statistically significant reduction of clinical decline. All key secondary endpoints were also met demonstrating highly statistically significant results, describes the company in a press release. Eisai will […]

The company’s study is published in the journal Obesity, and also chosen as “Editor’s Choice” for the November issue. The aim of Empros Pharma’s study was to evaluate the effect of a novel, oral, modified-release formulation of the lipase inhibitor orlistat and the glucosidase/amylase inhibitor acarbose (denoted EMP16) on relative body weight after 26 weeks compared […]

Cyxone has received approvals from the Medical Product Agency and the Central Ethics Committee in Poland to start a clinical Phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA). “The approval is a very important milestone for us. Cyxone have now finally the possibility to […]

AlzeCure Pharma has received new data from the clinical phase I study (multiple ascending dose, MAD) with repeated dosing of the drug candidate ACD856, which is being developed against Alzheimer’s disease and other indications with cognitive dysfunction. New data from a planned exploratory analysis of the MAD study show that ACD856 increases EEG activity in […]